文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

加巴喷丁类药物与手术患者阿片相关不良事件风险的关联

Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States.
PubMed 文献 · JAMA Netw Open · 2020-12-01
一句话结论大型手术患者围术期加巴喷丁类与阿片类联用与阿片过量风险升高相关(aHR 1.95),但绝对风险低。

主要终点阿片过量的校正风险比为1.95(95%CI 1.49-2.55),呼吸并发症、未特指阿片不良效应及复合终点的校正风险比分别为1.68、1.77和1.70。结论认为联用与阿片相关不良事件风险升高相关,但绝对风险较低。

要点

  • 大型手术成人手术当日起联用加巴喷丁类与阿片类,阿片过量校正风险比1.95(95%CI 1.49-2.55)。
  • 呼吸并发症校正风险比1.68(95%CI 1.59-1.78),未特指阿片不良效应为1.77(95%CI 1.61-1.93)。
  • 复合终点(过量、呼吸并发症、未特指不良效应)校正风险比1.70(95%CI 1.62-1.79)。

适用人群与场景

  • 排除标准原文未提及。

诊断标准与关键阈值

  • 暴露定义:手术当日开始加巴喷丁类(加巴喷丁或普瑞巴林)与阿片类联用,对比单用阿片类。
  • 主要终点为阿片过量;次要终点包括呼吸并发症、未特指阿片不良效应及三者复合终点。
  • 随访至术后30天、偏离初始治疗方案或出院(以先发生者为准)。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 联用加巴喷丁类与阿片类时需警惕阿片过量(校正风险比1.95)及呼吸并发症(校正风险比1.68)。
  • 需关注未特指阿片不良效应(校正风险比1.77)。

研究设计与关键结果

  • 呼吸并发症校正风险比1.68(95%CI 1.59-1.78);未特指阿片不良效应校正风险比1.77(95%CI 1.61-1.93);复合终点校正风险比1.70(95%CI 1.62-1.79)。
  • 敏感性分析和关键临床因素亚组结果一致。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(非随机对照试验)。
  • 局限:原文未明确提及证据等级;为观察性设计,可能存在残余混杂;绝对风险低。

对床旁实践的改变

  • 在大型手术患者中联用加巴喷丁类与阿片类时,应意识到阿片过量及呼吸并发症风险升高,尽管绝对风险低。
  • 不能因本研究的关联结果推断因果关系;原文未提供具体预防或监测方案。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: The use of gabapentinoids in multimodal postoperative analgesia is increasing; however, when coadministered with opioids, these drugs may potentiate central nervous system and respiratory depression.

OBJECTIVE: To evaluate the association between perioperative coadministration of gabapentinoids and opioids with inpatient opioid-related adverse events in surgical patients.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used propensity score trimming, stratification, and weighting of adults admitted for a major surgery between October 2007 and December 2017 who were treated with opioids on the day of surgery and included in the Premier Research database. Data analysis was conducted from February to April 2020.

EXPOSURE: Gabapentinoids (gabapentin or pregabalin) coadministered with opioids starting the day of surgery vs opioid therapy without gabapentinoids.

MAIN OUTCOMES AND MEASURES: Primary outcome was opioid overdose. Secondary outcomes included respiratory complications, unspecified adverse effects of opioid use, and a composite of these 3 outcomes. Patients were followed up for as long as 30 days from the day of surgery until deviation from the initial treatment regimen or discharge.

RESULTS: Gabapentinoids with opioids were administered to 892 484 of 5 547 667 eligible admissions (16.1%; mean [SD] age, 63.5 [11.8] years; 353 315 [39.6%] men). Among the 4 655 183 patients who received opioids only, the mean (SD) age was 63.7 (14.7) years, and 1 913 284 (41.1%) were men. Overall, 441 overdose events were identified, with absolute risks of 1.4 per 10 000 patients with gabapentinoid exposure and 0.7 per 10 000 patients receiving opioids only. Following propensity score trimming, the cohort included 737 383 patients exposed to gabapentinoids and 3 002 480 patients receiving opioids only. The primary analysis yielded the adjusted hazard ratio of 1.95 (95% CI, 1.49-2.55), and the number needed to treat for an additional overdose to occur was 16 914 patients (95% CI, 11 556-31 537 patients). Adjusted hazard ratios for secondary outcomes were 1.68 (95% CI, 1.59-1.78) for respiratory complications, 1.77 (95% CI, 1.61-1.93) for unspecified adverse effects of opioids, and 1.70 (95% CI, 1.62-1.79) for the composite outcome. The results were consistent across sensitivity analyses and subgroups identified by key clinical factors.

CONCLUSIONS AND RELEVANCE: In this real-world cohort study of patients who underwent major surgery, concomitant use of gabapentinoids with opioids was associated with increased risk of opioid overdose and other opioid-related adverse events; however, the absolute risk of adverse events was low.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Bykov K, Bateman BT, Franklin JM, et al. Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States. JAMA Netw Open. 2020. PMID: 33372975. doi:10.1001/jamanetworkopen.2020.31647

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。